Evorpacept

ALX Oncology's Q3 2023 Form 10-Q reports financial improvements, ongoing evorpacept trials, strategic initiatives, and challenges in advancing its CD47 checkpoint pathway therapies.

ALX Oncology's Phase 1b/2 trial results of evorpacept combined with zanidatamab in HER2-positive and HER2-low metastatic breast cancer accepted for poster spotlight at SABCS 2024, to be presented by Alberto J. Montero on Dec. 12.

ALX Oncology's Phase 1b/2 trial results of evorpacept combined with zanidatamab for HER2-positive and HER2-low metastatic breast cancer accepted for poster spotlight at SABCS, Dec 12.

CD47 inhibitor drugs in clinical trials aim to enhance cancer immunotherapy by targeting the CD47 surface checkpoint, which inhibits cancer proliferation. Despite no commercial approvals, several therapies are expected to enter the market soon, driven by increasing clinical trials and research, with the U.S. leading and China rapidly advancing in this field.

ALX Oncology Holdings Inc. develops Evorpacept [ALX148], a first-in-class CD47 inhibitor with an inactive Fc domain reducing side effects. ASPEN-06 Phase 2 trials combining Evorpacept with trastuzumab, ramucirumab, and paclitaxel (TRP) showed favorable results in HER2-positive gastric and gastroesophageal junction (GEJ) cancer. Evorpacept has FDA Fast Track designations for several indications, making the shares potentially bullish.

The Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028 report highlights the emergence of CD47 inhibition as a novel cancer immunotherapy, with multiple candidates in clinical trials, including magrolimab and evorpacept. The market is rapidly evolving, driven by rising cancer incidence and increased use of immunotherapies, with significant commercial interest and notable acquisitions. Challenges include managing toxicity and demonstrating therapeutic advantages over current treatments.